An observational study in Colorectal Cancer, sponsored by Asian Institute of Gastroenterology, India. Recruiting at 1 site in India. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Asian Institute of Gastroenterology, India · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Colorectal Neoplasms with a site in India — 8 open to participants now, 13 under way, 7 of them phase 3. Colorectal Neoplasms · India.
Among the 33 studies in Colorectal Neoplasms with a site in India, this one is one of 2 that started in 2026, is one of 5 observational ones, reaches primary completion later than 8 of the 12 other live ones, and was the 31st registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →8 of the 33 studies in Colorectal Neoplasms with a site in India are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in India, United States, Argentina and 22 more countries
Ages 18+
Pfizer · Sites in India, United States, Argentina and 17 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in India, United States, Australia and 23 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in India, United States, Belgium and 19 more countries
Ages 18+
Uppsala University · Sites in India, Sweden
Ages 18–79
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 10 · Phase 3 14 · Phase 4 2
First in 2006; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is below the median of 250 across 1,444 observational studies indexed under Colorectal Neoplasms.
Median enrollment 480 across the 28 interventional studies, 188 across the 5 observational. Of the 18 that completed or were terminated, 11 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 33 have an industry lead sponsor. The 10 most frequent:
Asian Institute of Gastroenterology, India is the lead sponsor of 135 studies on the registry; 59 are open to participants now.
Asian Institute of Gastroenterology, India has 2 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies in Colorectal Neoplasms with a site in India that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02754115Tata Memorial CentreAn Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy | 2026-12 |
| NCT04482309AstraZenecaA Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors | 2027-03-23 |
Add all 2 to your calendar (.ics) → With an account.
Among the 33 studies in Colorectal Neoplasms with a site in India, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Robotic-assisted surgeries are especially valuable for colorectal pathologies because they offer better vision and control for surgical manipulation given the narrow operative region within the pelvis .Some of the iatrogenic risk factors associated with higher post-operative adverse events following colorectal surgeries are surgeon experience' and hospital case load'. In order to mitigate these factors, surgical staplers have gained preference amongst surgeons due to their reproducible results and ease of learning At present there are only two methods of creating an anastomosis: hand-sewn technique using sutures or surgical staplers. Surgical staplers have been shown to be as effective as hand-sewn techniques for colorectal anastomoses However, anastomotic strictures can be bothersome for patients and the rate of stricture is fourfold higher for stapled anastomoses than for those that are hand sewn in colorectal anastomoses . Additionally, overzealous or incorrect stapling could also result in hemostasis or ischemia One of the most dreaded adverse events of colorectal resection is anastomotic leakages followed, in decreasing severity, by post-operative bleeding and ileus. Because of the severity of adverse events associated with an anastomotic leak, it is important to detect it early and provide early management for the same. However, diagnosis of anastomotic leakage is commonly a symptomatic diagnosis based on development of gas, purulent or fecal discharge from the drain, purulent discharge from the rectum, pelvic abscess or peritonitis. Such severe symptoms further complicate the post-operative recovery and lengthen the hospital stay. Interestingly, it has been
reported that anastomotic leaks were more often diagnosed late in the postoperative period and more often after hospital discharge, or 12 days postoperatively . Anastomotic leakage rates vary from the colon to the rectum, with much higher rates in the rectum. Because of the severity of adverse events associate with an anastomotic leak, there is a pressing need for new techniques for prevention of anastomotic leakages .
The criteria were revised on the registry on Oct 8, 2026. See what changed
200
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects undergoing robotic-assisted colorectal cancer surgery where AI-enabled SureForm™ Robotic.Stapler is used for bowel transection and/or creation of anastomosis.
Device: AI-enabled SureForm™ Robotic Stapler · Device: Conventional Laparoscopic Stapler
Subjects undergoing laparoscopic colorectal cancer surgery using conventional laparoscopic staplers for bowel transection and/or creation of anastomosis.
Device: AI-enabled SureForm™ Robotic Stapler · Device: Conventional Laparoscopic Stapler
Use of AI-enabled SureForm™ robotic stapler during robotic-assisted colorectal resections for transection and/or anastomosis creation.
Use of standard conventional laparoscopic staplers during laparoscopic colorectal resections for transection and/or anastomosis creation
Anastomotic leak rate
Percentage of participants diagnosed with an anastomotic leakage (confirmed clinically by gas, purulent/fecal discharge from the drain/rectum, pelvic abscess, peritonitis, or via radiological imaging/reoperation) following colorectal resection
Time frame: From time of surgery through 30 days post-operatively.
Percentage of Participants Requiring a Surgical Stapler Articulation Angle Greater Than 45 Degrees
Proportion of participants in whom surgical transection required a robotic wrist articulation angle exceeding 45 degrees (calculated as resultant 3D vector articulation: square root of pitch squared plus yaw squared). Additional telemetry parameters recorded include mean pitch and yaw angles, number of clamping attempts, and successful firing completion rates.
Time frame: Intra-operative (during the surgical procedure)
Other Complications Attributable to Stapler Use
Time frame: From intra-operative procedure through 30 days post-operatively.
Operative time
Operative time is defined as the total duration of the surgical procedure, measured in minutes, from skin incision to completion of skin closure.
Time frame: 24 MONTHS
Increase in Operative Time Due to Stapling Complications
Additional intra-operative time (in minutes) expended specifically to manage, troubleshoot, or repair staple-line-related issues or device malfunctions (such as over-sewing bleeding staple lines, applying hemostatic sealants, or redoing an anastomosis).
Time frame: Intra-operative (day of surgery).
Intraoperative and Postoperative Adverse Events
Rate and severity of procedure-related complications categorized according to the Clavien-Dindo classification system, including requirements for intra-operative or post-operative blood transfusion.
Time frame: From initiation of surgery through 30 days post-operatively.
Rate of Intracorporeal Anastomosis
Proportion of cases where the bowel anastomosis was constructed completely intracorporeally versus extracorporeally.
Time frame: Intra-operative (day of surgery)
Surgical Conversion Rate
Percentage of minimally invasive procedures (robotic or laparoscopic) converted to an unplanned open laparotomy or hand-assisted approach.
Time frame: Intra-operative (day of surgery).
Conversion Rate Due to Stapling-Related Complications
Percentage of conversions to open surgery or hand-assisted techniques directly resulting from stapler misfires, device failure, or intractable staple-line failure.
Time frame: Intra-operative (day of surgery)
Length of ICU Stay
Total duration of intensive care unit admission recorded in continuous days.
Time frame: From immediate post-operative transfer until discharge from the ICU (assessed up to 30 days post-surgery).
Increase in ICU Stay Due to Stapling Complications
Additional days spent in the intensive care unit directly attributable to the management and recovery from staple-line leaks, bleeding, or reinterventions.
Time frame: From immediate post-operative period through hospital discharge (assessed up to 30 days post-surgery).
Total Length of Hospital Stay
Time frame: From date of surgery through index hospital discharge (assessed up to 30 days post-surgery).
Increase in Hospital Stay Due to Stapling Complications
Time frame: Through index hospital discharge (assessed up to 30 days post-surgery).
Resection Margin Positivity Rate
Time frame: Through final histopathology reporting (typically within 14 to 30 days post-surgery).
Percentage of Participants With Complete Mesorectal Excision Quality Graded by Quirke Classification
Time frame: Through final histopathology reporting (typically within 14 to 30 days post-surgery).
Number of Regional Lymph Nodes Harvested per Participant
Total count of regional lymph nodes harvested and histopathologically examined from the resected colorectal surgical specimen. Data will be reported as the mean or median number of lymph nodes retrieved per participant.
Time frame: Through final histopathology reporting (typically within 14 to 30 days post-surgery).
30-Day Hospital Readmission Rate
Time frame: From hospital discharge up to 30 days post-surgery.
30-Day Reoperation Rate
Time frame: From completion of surgery through 30 days post-surgery.
Time to Initiation of Adjuvant Therapy
Time frame: From date of surgery up to 30 days post-surgery (or standard post-operative follow-up window).
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Feb 2028, 25 months after the start.
Of 531 non-industry observational studies under Colorectal Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 132. This study's planned 25 months is below that.
Counting every sponsor, half of 648 studies reached it within 52 months; a quarter within 27 and three quarters within 104.
Start moved once since we started tracking on Sep 25, 2026: Feb 2026 → Jan 2026, on Oct 8, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Asian Institute of Gastroenterology, India →